Stock ABVC ABVC BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
1.08 USD -6.09% Intraday chart for ABVC BioPharma, Inc. -23.94% -6.90%
04-10 ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc CI
03-26 ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 427.9 83.92 104.7 96.05 20.22 8.951
Enterprise Value (EV) 1 429.5 88.69 107.2 93.46 23.48 11.26
P/E ratio -100 x -23 x -10.2 x -6.62 x -1.2 x -0.48 x
Yield - - - - - -
Capitalization / Revenue - 119,586,790 x 216,846,580 x 269,964,038 x 20,853,234 x 58,721,374 x
EV / Revenue - 126,395,875 x 221,999,261 x 262,664,829 x 24,208,439 x 73,880,417 x
EV / EBITDA - -26,058,288 x -12,662,684 x -7,991,753 x -1,555,731 x -1,375,381 x
EV / FCF 181 x -9.42 x -42.9 x -20.2 x -11.9 x -4.06 x
FCF Yield 0.55% -10.6% -2.33% -4.96% -8.39% -24.6%
Price to Book -74.4 x -556 x 35.8 x 11 x 6.57 x 1.09 x
Nbr of stocks (in thousands) 1,188 1,920 2,054 2,833 3,236 7,716
Reference price 2 360.0 43.70 51.00 33.90 6.250 1.160
Announcement Date 19-04-15 20-05-15 21-03-16 22-03-31 23-03-31 24-03-13
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 0.7017 0.483 0.3558 0.9698 0.1524
EBITDA - -3.404 -8.469 -11.69 -15.09 -8.188
EBIT 1 -1.394 -3.459 -8.506 -11.71 -15.11 -8.217
Operating Margin - -492.9% -1,760.87% -3,290.07% -1,558.54% -5,390.35%
Earnings before Tax (EBT) 1 -4.099 -4.01 -10.81 -11.21 -15.51 -10.65
Net income 1 -4.101 -3.642 -9.791 -12.84 -16.42 -10.52
Net margin - -518.98% -2,026.97% -3,608.47% -1,693.5% -6,898.68%
EPS 2 -3.600 -1.896 -5.000 -5.125 -5.200 -2.430
Free Cash Flow 1 2.379 -9.415 -2.499 -4.631 -1.969 -2.772
FCF margin - -1,341.72% -517.37% -1,301.69% -203.07% -1,818.84%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-04-15 20-05-15 21-03-16 22-03-31 23-03-31 24-03-13
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 0.099 -0.04 - 0.3129 0.0423 0.589 0.1283
EBITDA - - - - - - -
EBIT -1.971 -6.447 - -2.047 -3.716 -3.133 -
Operating Margin -1,990.45% 16,117.87% - -654.24% -8,790.73% -531.93% -
Earnings before Tax (EBT) -1.962 -5.89 - -2.03 -3.772 -3.538 -
Net income -1.806 -7.932 -5.995 -1.859 -3.705 -4.864 -
Net margin -1,824.74% 19,830.62% - -594.2% -8,764.75% -825.81% -
EPS 2 -0.7000 -3.100 -2.000 -0.6000 -1.100 -1.500 -0.6000
Dividend per Share - - - - - - -
Announcement Date 21-11-15 22-03-31 22-05-16 22-08-15 22-11-14 23-03-31 23-05-15
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1.66 4.78 2.49 - 3.25 2.31
Net Cash position 1 - - - 2.6 - -
Leverage (Debt/EBITDA) - -1.404 x -0.2939 x - -0.2156 x -0.2822 x
Free Cash Flow 1 2.38 -9.42 -2.5 -4.63 -1.97 -2.77
ROE (net income / shareholders' equity) 109% 144% -835% -209% -269% -192%
ROA (Net income/ Total Assets) -63.6% -33.6% -57.4% -57.8% -80.2% -42.7%
Assets 1 6.45 10.84 17.07 22.2 20.47 24.65
Book Value Per Share 2 -4.840 -0.0800 1.420 3.090 0.9500 1.060
Cash Flow per Share 2 0.0300 0.0800 1.770 2.030 0.0300 0.0100
Capex - - - 0.02 0.12 0.02
Capex / Sales - - - 4.92% 12.34% 13.91%
Announcement Date 19-04-15 20-05-15 21-03-16 22-03-31 23-03-31 24-03-13
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.08
Average target price
-
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABVC BIOPHARMA, INC. Stock ABVC BioPharma, Inc.
-6.90% 11.38M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABVC Stock
  4. Financials ABVC BioPharma, Inc.